Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer
出版年份 2012 全文链接
标题
Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer
作者
关键词
-
出版物
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 16, Issue 8, Pages 771-781
出版商
Informa Healthcare
发表日期
2012-07-05
DOI
10.1517/14728222.2012.697155
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors
- (2012) Gargi Ghosh et al. BMC CANCER
- Exploring the cancer genome in the era of next-generation sequencing
- (2012) Hui Dong et al. Frontiers of Medicine
- A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations
- (2011) Gregory J. Riely et al. Journal of Thoracic Oncology
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer
- (2010) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
- (2010) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers
- (2010) Ryoichi Onozato et al. Journal of Thoracic Oncology
- Inducible EGFR T790M-Mediated Gefitinib Resistance in Non-small Cell Lung Cancer Cells Does Not Modulate Sensitivity to PI103 Provoked Autophagy
- (2010) Flavia F. Moreira-Leite et al. Journal of Thoracic Oncology
- Status of PI3K inhibition and biomarker development in cancer therapeutics
- (2009) B. Markman et al. ANNALS OF ONCOLOGY
- Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer
- (2009) T. Yamada et al. CLINICAL CANCER RESEARCH
- A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors
- (2009) K.-K. Wong et al. CLINICAL CANCER RESEARCH
- Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
- (2009) W. Wang et al. CLINICAL CANCER RESEARCH
- Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status
- (2009) Takamitsu Onitsuka et al. LUNG CANCER
- Cancer Statistics, 2008
- (2008) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations
- (2008) S. Yano et al. CANCER RESEARCH
- Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer
- (2008) Katsuhiro Okuda et al. CANCER SCIENCE
- Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment
- (2008) T. M. Chin et al. CLINICAL CANCER RESEARCH
- METgene amplification orEGFRmutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors
- (2008) Takafumi Kubo et al. INTERNATIONAL JOURNAL OF CANCER
- Somatic Mutations of ErbB4
- (2008) Denis Tvorogov et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan
- (2008) Toshimi Takano et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib (ZD1839): Therapy in selected patients with non-small cell lung cancer (NSCLC)?
- (2008) Diego Dongiovanni et al. LUNG CANCER
- Somatic mutations affect key pathways in lung adenocarcinoma
- (2008) Li Ding et al. NATURE
- Activation of tyrosine kinases by mutation of the gatekeeper threonine
- (2008) Mohammad Azam et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- (2008) C.-H. Yun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started